Quantcast

Bayer’s CONTOUR and Bayer’s BREEZE2 Blood Glucose Monitoring Systems Do Not Use Problematic GDH-PQQ Technology

August 14, 2009

TARRYTOWN, N.Y., Aug. 14 /PRNewswire/ The U. S. Food and Drug Administration issued Advice for Diabetic Patients and their Caregivers on August 13, stating that blood glucose meters that use GDH-PQQ technology may “produce a falsely high (elevated) blood glucose result.” Since 2006, Bayer Diabetes Care has not distributed test strips that use GDH-PQQ (glucose dehydrogenase pyrroloquinoline quinone) glucose monitoring technology for its blood glucose meters.

Bayer Diabetes Care is committed to patient safety and has a portfolio of blood glucose meters that all meet the current FDA requirements. The company adheres to and supports the highest standard of quality in its meters and strives to do everything possible by a manufacturer to ensure the accuracy of readings. Bayer Diabetes Care meters are designed to minimize the impact from as many external variants as possible, helping to ensure accuracy of readings. Bayer’s BREEZE(R)2 and CONTOUR(R) systems both feature No Coding(TM) technology, and no interference with common substances including the non-glucose sugars maltose and galactose.

For more information on Bayer Diabetes Care blood glucose monitoring systems, visit www.bayerdiabetes.com.

SOURCE Bayer Diabetes Care


Source: newswire



comments powered by Disqus